Meningococcal – (MenACWY-CRM ≥2 mos)
Recommended Age Range:
≥2 months (depending on risk factors)
Common Side Effects:
Soreness, fever, headache, irritability, vomiting
Research & Testing History:
Licensed 2010; trials showed robust immune response in infants and children.
Use History:
Use since 2010
Trial Size:
3 randomized clinical studies of ~9,000 infants
Years on Schedule:
~15 years
Known Safety Concerns:
Very rare adverse reactions
Ingredients:
- Diphtheria CRM197 protein conjugated to Neisseria meningitidis serogroups A, C, W-135, and Y polysaccharides; excipients: sodium chloride, histidine, sucrose; residuals: formaldehyde, polysorbate 80Havrix: Inactivated hepatitis A virus; adjuvant: aluminum hydroxide; stabilizers: amino acid supplement, phosphate-buffered saline solution, polysorbate 20; residuals: proteins from MRC-5 human cells, formalin, neomycin sulfate